SAN DIEGO, Jan. 10, 2018 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company
focused on unmet needs in global health and biodefense, today
announced the appointment of Sabrina
Martucci Johnson to its Board of Directors and to its Audit
Committee. Ms. Johnson qualifies as an independent director under
the Nasdaq Rules.
"We are very pleased to have Sabrina join the Aethlon team,"
stated Aethlon Medical founder and CEO, Jim
Joyce. "With the recent "Breakthrough Device" designation of
our Hemopurifier, Sabrina's
appointment reflects our focus to build a Board of Directors with
relevant experience in transitioning clinical-stage therapies to
the marketplace."
"I am pleased to be joining the board and assisting in the
strategy to bring the Aethlon Hemopurifier® therapeutic device to market,"
stated Sabrina Martucci Johnson. "It
is an honor to work on a program that has the opportunity to
address life-threatening viral infections that are not addressed
with approved therapies."
Sabrina Martucci Johnson is the
Founder and CEO of DARÉ Bioscience (NASDAQ:DARE), a healthcare
company committed to the development and commercialization of
innovative products in women's reproductive health. Prior to
founding DARÉ, Sabrina was President of WomanCare Global
Trading, a global provider of women's health products, and
CFO/CAO of the California Institute for Biomedical Research.
She served as COO and CFO of Cypress Bioscience, Inc., the
developer of the PROSORBA column, where she launched and secured a
global partner for that apheresis product until its sale for
$250 million in 2010. She also held
sales and marketing positions with Advanced Tissue Sciences and
Clonetics Corporation. She began her career in the
biotechnology industry as a research scientist with Baxter
Healthcare.
In the community Sabrina serves on the board of organizations
that advance the economic well-being and health of women and girls
and promote education. She serves on the YWCA of
San Diego County Board of
Directors as immediate past-president, Clearity Foundation Board of
Directors, Athena Board of Directors
as Co-Chair, Tulane University School
of Science & Engineering Board of Advisors, University
California San Diego Librarian's Advisory Board, Project Concern
International Audit Committee, and Sabrina is the immediate past
co-president of Women Give San Diego.
Sabrina has a Master of International Management with honors
from the American Graduate School of
International Management (Thunderbird); a MSc. in
Biochemical Engineering from the University of London, University College London; and a BSc.
in Biomedical Engineering from Tulane
University, magna cum laude.
About Aethlon Medical, Inc.
Aethlon Medical is focused on addressing unmet needs in global
health and biodefense. The Aethlon Hemopurifier® is a
first-in-class therapeutic device designed to address
life-threatening viral infections. The United States Food and
Drug Administration (FDA) has designated the Hemopurifier® as
a Breakthrough Device related to the treatment of life-threatening
viruses that are not addressed with approved therapies.
In collaboration with leading government and non-government
research institutes, Aethlon has validated the ability of the
Hemopurifier® to capture a broad-spectrum of pandemic influenza
viruses, mosquito-borne viruses and deadly hemorrhagic
viruses. Based on its use to treat Ebola virus, the
Hemopurifier® was named a "Top 25 Invention" and one of the "Eleven
Most Remarkable Advances in Healthcare," by TIME Magazine.
Aethlon is also investigating the potential therapeutic use of
the Hemopurifier® to reduce the presence of tumor-derived exosomes,
which contribute to immune-suppression and the spread of metastasis
in cancer patients. Additionally, Aethlon is the majority
owner of Exosome Sciences, Inc. (ESI), which is focused on the
discovery of exosomal biomarkers to diagnose and monitor cancer and
neurological disorders, including Alzheimer's disease (AD) and
Chronic Traumatic Encephalopathy (CTE). Additional
information can be found online at www.AethlonMedical.com and
www.ExosomeSciences.com. You can also connect with us on
Twitter, LinkedIn, Facebook and Google+.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve
risks and uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect," "intend," "plan," "project,"
"will," "projections," "estimate," or similar expressions
constitute forward-looking statements. Forward-looking statement
includes statements relating to the public offering and the
satisfaction of closing conditions relating to the public offering,
as well as general economic and market factors. Such
forward-looking statements are subject to significant risks and
uncertainties and actual results may differ materially from the
results anticipated in the forward-looking statements. Factors that
may contribute to such differences include, without limitation, the
Company's ability to maintain its listing on the Nasdaq Capital
Market, or any other national securities exchange, that the Company
or its subsidiary will not be able to commercialize its products,
that the FDA will not approve the initiation or continuation of the
Company's clinical programs or provide market clearance of the
Company's products, the Company's ability to raise capital when
needed, the Company's ability to complete the development of its
planned products, the Company's ability to manufacture its products
either internally or through outside companies, the impact of
government regulations, patent protection on the Company's
proprietary technology, the ability of the Company to meet the
milestones contemplated in its contract with DARPA, product
liability exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. The foregoing list of
risks and uncertainties is illustrative, but is not exhaustive.
Additional factors that could cause results to differ materially
from those anticipated in forward-looking statements can be found
under the caption "Risk Factors" in the Company's Annual Report on
Form 10-K for the year ended March 31,
2017, and in the Company's other filings with the
Securities and Exchange Commission. Except as may be required by
law, the Company does not intend, nor does it undertake any duty,
to update this information to reflect future events or
circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 extension 3300
Jfrakes@aethlonmedical.com
Investor Relations:
John Marco
CORE IR
516 222 2560
johnm@coreir.com
View original
content:http://www.prnewswire.com/news-releases/sabrina-martucci-johnson-joins-aethlon-medicals-board-of-directors-300580308.html
SOURCE Aethlon Medical, Inc.